Analyst Price Target is GBX 307.17
▲ +7.25% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ConvaTec Group in the last 3 months. The average price target is GBX 307.17, with a high forecast of GBX 323 and a low forecast of GBX 300. The average price target represents a 7.25% upside from the last price of GBX 286.40.
Current Consensus is
Buy
The current consensus among 6 investment analysts is to buy stock in ConvaTec Group. This Buy consensus rating has held steady for over two years.
ConvaTec Group PLC engages in the development, manufacture, and marketing of medical products and technologies worldwide. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence and critical care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.
Read More